Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPS21-DT (RPS21 divergent transcript) is classified as a long non-coding RNA (lncRNA) transcribed divergently from the promoter region of the protein-coding RPS21 gene. Divergent transcription is a common phenomenon in mammalian genomes, with many lncRNAs transcribed antisense to nearby protein-coding genes. These divergent lncRNAs are often associated with genes involved in transcriptional regulation and development, potentially playing roles in fine-tuning gene expression. As a non-coding RNA, RPS21-DT does not encode a functional protein and is not recognized as a canonical therapeutic target (e.g., receptor, enzyme, transporter). Its molecular function and clinical significance remain largely uncharacterized, and it is not currently associated with particular drugs, disease roles, or biomarker status. If structured information is required, this would return a null or “not a target” entry for most database fields describing traditional drug targets. RPS21-DT is not misspelled or otherwise incorrect, but inclusion as a target is only appropriate in studies of non-coding RNA function or regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RPS21 divergent transcript (RPS21-DT).